stocksASPIRA
ASPIRA

Aspira Pathlab & Diagnostics Ltd.

106.90-2.1 (-1.97%)
7 Aug, 12:00 AM

Income Statement

Abridged
Understanding Income Statement
Aspira Pathlab & Diagnostics Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.
2013
Mar 31
2014
Mar 31
2015
Mar 31
2016
Mar 31
R
2017
Mar 31
2018
Mar 31
2019
Mar 31
2020
Mar 31
2021
Mar 31
2022
Mar 31
2023
Mar 31
2024
Mar 31
2025
Mar 31
2026
Mar 31
Period length:
Source:
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
PRESS
Total Revenue
0.040.04--0.764.367.648.4215.2119.5414.4613.2022.0024.98
Cost of Operating Revenue
----0.342.853.483.654.084.774.084.165.196.06
Gross Profit
0.040.04--0.421.514.154.7711.1314.7710.379.0416.8118.92
Gross Margin
100.0100.0--55.034.654.456.773.275.671.868.576.475.7
Total Operating Expenses
0.010.020.140.243.539.3612.1111.9013.1414.8014.4515.9319.9725.06
Operating Profit
0.030.02-0.14-0.24-2.78-5.00-4.48-3.492.074.740.01-2.732.03-0.08
Operating Margin
72.059.4---365.8-114.7-58.6-41.413.624.20.1-20.69.2-0.3
Financing Income/(Expense) - Net
----0.05-0.26-0.80-0.96-1.01-0.89-0.37-0.42-0.37-0.35-0.39
Profit before Taxes
0.030.020.070.04-2.72-5.58-5.18-4.211.384.46-0.09-2.672.070.05
Income Taxes
0.010.010.040.010.00-0.000.03------
Profit after Tax
0.020.020.020.03-2.72-5.58-5.18-4.241.384.46-0.09-2.672.020.05
PAT Margin
46.841.1---359.1-128.1-67.9-50.49.122.8-0.6-20.29.20.2
EPS - Basic - ex Extraordinary Items
0.040.030.040.05-5.25-10.75-6.33-4.951.454.33-0.09-2.601.970.05
EPS - Diluted - ex Extraordinary Items
0.040.030.040.05-5.25-10.75-6.33-4.951.454.33-0.09-2.601.970.05
EBIT
0.030.02-0.14-0.24-2.78-5.00-4.48-3.492.074.740.01-2.732.03-0.08
EBITDA
0.030.02-0.14-0.24-2.58-3.87-3.25-1.833.516.371.59-1.193.521.46
EBITDA Margin
72.059.4---339.5-88.9-42.5-21.723.132.611.0-9.016.05.9

Balance Sheet

Abridged
Understanding Balance Sheet
Aspira Pathlab & Diagnostics Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.
2013
Mar 31
2014
Mar 31
2015
Mar 31
C
2016
Mar 31
R
2017
Mar 31
2018
Mar 31
2019
Mar 31
2020
Mar 31
2021
Mar 31
2022
Mar 31
2023
Mar 31
2024
Mar 31
2025
Mar 31
2026
Mar 31
Source:
AR
AR
AR
AR
AR
AR
AR
AR
AR
AR
AR
AR
AR
PRESS
Total Current Assets
0.610.633.825.743.981.792.303.293.887.145.864.365.364.59
Long-Term Investments
------3.252.25-1.080.350.352.223.13
Property Plant & Equipment - Net
---0.046.946.856.196.044.966.825.314.123.863.88
Total Non-Current Assets
---0.5510.8810.7412.5011.057.9010.9911.4910.3512.1013.92
Total Assets
0.610.633.826.3014.8612.5314.8014.3411.7818.1417.3414.7117.4618.51
Total Current Liabilities
0.000.000.212.665.751.644.215.122.011.791.582.072.373.20
Long Term Debt
----3.1710.504.785.191.253.272.642.082.372.44
Total Non-Current Liabilities
---0.003.1910.565.405.411.453.563.012.502.923.08
Total Liabilities
0.000.000.212.668.9412.209.6110.533.465.354.594.575.306.27
Total Shareholders' Equity
0.610.633.613.645.920.335.193.808.3112.7912.7510.1412.1712.23
Total Equity
0.610.633.613.645.920.335.193.808.3112.7912.7510.1412.1712.23
Total Liabilities & Equity
0.610.633.826.3014.8612.5314.8014.3411.7818.1417.3414.7117.4618.51

Cash Flow

Abridged
Understanding Cash Flow Statement
Aspira Pathlab & Diagnostics Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.
2013
Mar 31
2014
Mar 31
2015
Mar 31
2016
Mar 31
C
2017
Mar 31
R
2018
Mar 31
R
2019
Mar 31
2020
Mar 31
2021
Mar 31
2022
Mar 31
2023
Mar 31
2024
Mar 31
2025
Mar 31
2026
Mar 31
Period length:
Source:
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
IR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
PRESS
Operating CF bef Changes in Working Cap
-0.010.010.22-0.17-2.53-4.46-3.94-2.563.056.581.59-0.873.821.99
Working Capital - Increase/(Decrease)
---0.20-0.171.29-0.94-0.15-0.031.93-4.83-1.731.96-1.97-0.41
Net CF from Operating Activities
-0.010.010.03-0.34-1.24-5.40-4.09-2.594.991.75-0.141.091.851.58
Capital Expenditures - Net
----7.121.000.510.050.300.610.140.260.340.70
Net CF from Investing Activities
0.16-0.130.062.60-10.45-1.00-2.22-0.05-0.30-0.61-0.13-0.26-0.25-1.32
Stock - Issuance/(Retirement) - Net
--2.960.005.00-5.102.863.00-----
Debt - LT & ST - Issuance/(Retirement) - Total
----4.167.331.09-0.58-4.28-0.98-0.52-0.59-0.65-0.75
Net Cash Flow from Financing Activities
--2.960.009.167.336.192.28-1.28-0.98-0.52-0.59-0.65-0.75
Free Cash Flow to Equity
-----4.200.94-3.52-3.210.410.17-0.790.240.860.13
Free Operating CF net dividend
-0.010.010.03-0.34-8.36-6.39-4.60-2.644.691.15-0.270.821.500.88
Free Operating CF
-0.010.010.03-0.34-8.36-6.39-4.60-2.644.691.15-0.270.821.500.88

Business Segment Analysis

Aspira Pathlab & Diagnostics Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

We don't have enough data to show business segment analysis for Aspira Pathlab & Diagnostics Ltd.

Regional Segment Analysis

Aspira Pathlab & Diagnostics Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Aspira Pathlab & Diagnostics Ltd.

Historical Segment Analysis

Track how Aspira Pathlab & Diagnostics Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

We don't have enough data to show segments for Aspira Pathlab & Diagnostics Ltd.

Frequently Asked Questions

What is the revenue of Aspira Pathlab & Diagnostics Ltd.?
The latest trailing twelve month revenue of Aspira Pathlab & Diagnostics Ltd. is ₹ 24.98 Cr, reflecting a 1-year growth of 13.56% and a 3-year CAGR of 20.00%. Annual and quarterly revenue trends are available in the Income Statement section.
What is the net profit of Aspira Pathlab & Diagnostics Ltd.?
The latest trailing twelve month net profit (PAT) of Aspira Pathlab & Diagnostics Ltd. is ₹ 0.05 Cr. Detailed profit history across annual and quarterly periods is in the Income Statement section.
What is the EBITDA of Aspira Pathlab & Diagnostics Ltd.?
The trailing twelve month EBITDA of Aspira Pathlab & Diagnostics Ltd. is approximately ₹ -0.08 Cr (based on an operating margin of -0.30%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.
What is the EPS of Aspira Pathlab & Diagnostics Ltd.?
The trailing twelve month Earnings Per Share (EPS) of Aspira Pathlab & Diagnostics Ltd. is 0.05. EPS trends across annual and quarterly periods are visible in the Income Statement section.
What is the debt level of Aspira Pathlab & Diagnostics Ltd.?
The debt-to-equity ratio of Aspira Pathlab & Diagnostics Ltd. stands at 0.27. The interest coverage ratio is -0.19x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.
What is the book value per share of Aspira Pathlab & Diagnostics Ltd.?
The estimated book value per share of Aspira Pathlab & Diagnostics Ltd. is 11.88 (derived from a P/B ratio of 9.00 and market price of ₹ 106.90), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.
What is the cash flow from operations of Aspira Pathlab & Diagnostics Ltd.?
The trailing twelve month operating cash flow of Aspira Pathlab & Diagnostics Ltd. is ₹ 1.58 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.
Does Aspira Pathlab & Diagnostics Ltd. report consolidated or standalone financials?
Aspira Pathlab & Diagnostics Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.